Systemic mastocytosis

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
3 Unique sponsors
6 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
D Dermatology (ATC D) 1
R Respiratory (ATC R) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Kinase inhibitor 1 substance
Monoclonal antibody 1 substance
Supportive / diluent 1 substance
Phase III: 1 Phase II: 2 Phase I/II: 1 Phase IV: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Medical University Of Gdansk Academic
    DUPILUMAB; FEXOFENADINE HYDROCHLORIDE; SODIUM CHLORIDE
    2023-509111-89-00 1 country 2025 n=66
    Recruiting

Phase II

2 trials
  • Blueprint Medicines Corp. Commercial
    AVAPRITINIB
    2024-512585-34-00 9 countries 2019 n=114 Orphan
    Ended
  • Cogent Biosciences Inc. Commercial
    3,4-DIMETHYL-N-(2-PHENYL-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLE-5-CARBOXAMIDE
    2022-501427-24-00 12 countries 2023 n=128
    Recruiting

Phase I/II

1 trial
  • Blueprint Medicines Corp. Commercial
    BLU-263 PHOSPHATE
    2023-510144-20-00 6 countries 2023 n=41 Orphan
    Ended

Phase IV

1 trial
  • Blueprint Medicines Corp. Commercial
    AVAPRITINIB
    2024-514969-18-00 4 countries 2024 n=26
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Blueprint Medicines Corp. Commercial 3 Phase II, Phase IV, Phase I/II 1
Cogent Biosciences Inc. Commercial 1 Phase II 1
Medical University Of Gdansk Academic 1 Phase III 1
New trials by year
2019
1
2023
2
2024
1
2025
1
← All indication landscapes